Pazdur on pandemonium: calls for collaboration, competition on PD-1 drugs

Pazdur chastizes PD-1/PD-L1 pharmas for losing sight of patients

In separate sessions at AACR, FDA’s Oncology chief Richard Pazdur’s pointed comments and questions to PD-1/PD-L1 companies made it clear that he thinks patients are getting hurt from pharmas’ failure to collaborate and the high drug prices they’re demanding.

At the American Association for Cancer Research meeting, the Oncology Center of Excellence Director called on Western companies to collaborate on platform trials and encouraged Chinese companies to compete in the U.S. on price.

During a session on April 1 titled “PD-1 Pandemonium,” Pazdur pressed representatives from companies with marketed PD-1/PD-L1 inhibitors to explain why they aren’t collaborating more in the clinic, while questioning whether there are too many of these drugs on the market.

Pazdur chastised companies for failing to work together to develop biomarkers and conduct platform trials, suggesting it was an inefficient use of the healthcare system’s most precious stakeholders, patients.

“Patients are not a company’s resource. They’re a global resource and this inefficiency gives them a lack of confidence in the system.”

Richard Pazdur, FDA

Two days

Read the full 1683 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE